IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.
Identifieur interne : 002007 ( Main/Exploration ); précédent : 002006; suivant : 002008IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.
Auteurs : Toshio TanakaSource :
- Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology [ 1349-7413 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux humanisés (usage thérapeutique), Arthrite juvénile (traitement médicamenteux), Découverte de médicament, Humains, Inflammation (traitement médicamenteux), Inflammation (étiologie), Interleukine-6 (immunologie), Interleukine-6 (physiologie), Polyarthrite rhumatoïde (traitement médicamenteux), Souris, Thérapie moléculaire ciblée.
- MESH :
- immunologie : Interleukine-6.
- physiologie : Interleukine-6.
- traitement médicamenteux : Arthrite juvénile, Inflammation, Polyarthrite rhumatoïde.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- étiologie : Inflammation.
- Animaux, Découverte de médicament, Humains, Souris, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal, Humanized (therapeutic use), Arthritis, Juvenile (drug therapy), Arthritis, Rheumatoid (drug therapy), Castleman Disease (drug therapy), Drug Discovery, Humans, Inflammation (drug therapy), Inflammation (etiology), Interleukin-6 (immunology), Interleukin-6 (physiology), Mice, Molecular Targeted Therapy.
- MESH :
- chemical , immunology : Interleukin-6.
- chemical , physiology : Interleukin-6.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- drug therapy : Arthritis, Juvenile, Arthritis, Rheumatoid, Castleman Disease, Inflammation.
- etiology : Inflammation.
- Animals, Drug Discovery, Humans, Mice, Molecular Targeted Therapy.
Abstract
Interleukin-6 (IL-6) is a prototypical cytokine featuring pleiotropic and redundant activity. It is an essential factor to protect host from environmental stress and to maintain homeostasis, whereas its dysregulated, excessive or persistent production plays a pathological role in various inflammatory diseases. Then, IL-6 blockade was expected to become a novel therapeutic strategy and a humanized anti-IL-6 receptor antibody, tocilizumab was developed. Indeed, through clinical trials its efficacy and tolerable safety was proved and is now in clinical use for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis and Castleman's disease. Moreover, ongoing various clinical studies suggest that it will be widely applicable for the treatment of intractable chronic immune-mediated diseases as well as acute severe inflammatory diseases presenting with "cytokine storm".
DOI: 10.2177/jsci.38.433
PubMed: 27118330
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001257
- to stream PubMed, to step Curation: 001257
- to stream PubMed, to step Checkpoint: 001104
- to stream Ncbi, to step Merge: 001156
- to stream Ncbi, to step Curation: 001156
- to stream Ncbi, to step Checkpoint: 001156
- to stream Main, to step Merge: 002007
- to stream Main, to step Curation: 002007
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.</title><author><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name><affiliation><nlm:affiliation>Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University.</nlm:affiliation><wicri:noCountry code="subField">Osaka University</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:27118330</idno><idno type="pmid">27118330</idno><idno type="doi">10.2177/jsci.38.433</idno><idno type="wicri:Area/PubMed/Corpus">001257</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001257</idno><idno type="wicri:Area/PubMed/Curation">001257</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001257</idno><idno type="wicri:Area/PubMed/Checkpoint">001104</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001104</idno><idno type="wicri:Area/Ncbi/Merge">001156</idno><idno type="wicri:Area/Ncbi/Curation">001156</idno><idno type="wicri:Area/Ncbi/Checkpoint">001156</idno><idno type="wicri:Area/Main/Merge">002007</idno><idno type="wicri:Area/Main/Curation">002007</idno><idno type="wicri:Area/Main/Exploration">002007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.</title><author><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name><affiliation><nlm:affiliation>Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University.</nlm:affiliation><wicri:noCountry code="subField">Osaka University</wicri:noCountry></affiliation></author></analytic><series><title level="j">Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology</title><idno type="eISSN">1349-7413</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Arthritis, Juvenile (drug therapy)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Castleman Disease (drug therapy)</term><term>Drug Discovery</term><term>Humans</term><term>Inflammation (drug therapy)</term><term>Inflammation (etiology)</term><term>Interleukin-6 (immunology)</term><term>Interleukin-6 (physiology)</term><term>Mice</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Arthrite juvénile (traitement médicamenteux)</term><term>Découverte de médicament</term><term>Humains</term><term>Inflammation (traitement médicamenteux)</term><term>Inflammation (étiologie)</term><term>Interleukine-6 (immunologie)</term><term>Interleukine-6 (physiologie)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Souris</term><term>Thérapie moléculaire ciblée</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Juvenile</term><term>Arthritis, Rheumatoid</term><term>Castleman Disease</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Interleukine-6</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Interleukine-6</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite juvénile</term><term>Inflammation</term><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Inflammation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Discovery</term><term>Humans</term><term>Mice</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Découverte de médicament</term><term>Humains</term><term>Souris</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interleukin-6 (IL-6) is a prototypical cytokine featuring pleiotropic and redundant activity. It is an essential factor to protect host from environmental stress and to maintain homeostasis, whereas its dysregulated, excessive or persistent production plays a pathological role in various inflammatory diseases. Then, IL-6 blockade was expected to become a novel therapeutic strategy and a humanized anti-IL-6 receptor antibody, tocilizumab was developed. Indeed, through clinical trials its efficacy and tolerable safety was proved and is now in clinical use for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis and Castleman's disease. Moreover, ongoing various clinical studies suggest that it will be widely applicable for the treatment of intractable chronic immune-mediated diseases as well as acute severe inflammatory diseases presenting with "cytokine storm".</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Tanaka, Toshio" sort="Tanaka, Toshio" uniqKey="Tanaka T" first="Toshio" last="Tanaka">Toshio Tanaka</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27118330
|texte= IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27118330" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |